News
India’s patent laws coming under repeated challenges
2012-11-15 India’s patent laws are being challenged by Big Pharma. Novartis is challenging India for denying the pharma giant a patent for Glivec (imatinib mesylate), its… Read More »
Maximising the potential of generics in Abu Dhabi
2012-11-13 IntroductionAll residents in Abu Dhabi have access to health care via mandatory health insurance. Nationals, who comprise 20% of the population with two-thirds under 30… Read More »
Coupons help Big Pharma to fend off generics
2012-11-08 Pfizer’s success at using co-pay coupons to prevent patients switching from brand-name products to generics is encouraging other pharmaceutical giants to follow suit. When its… Read More »
Growing economies, growing markets: a bright future for biosimilars
2012-11-05 The biosimilars market, currently small and focused on a few disease areas and countries, is likely to grow considerably over the coming years, particularly in… Read More »
Biosimilar comparability debate continues
2012-11-01 Authors Schellekens and Moors comment on the response from EMA’s Biosimilar Medicinal Products Working Party to questions that they raised regarding EMA’s comprehensive biosimilar regulatory… Read More »
Facts about generics for patients
2012-10-29 The costs of health care are rising across Europe through ageing populations resulting in more patients with chronic diseases, stricter clinical targets for managing patients… Read More »
Positioning of biosimilars: commodity versus differentiated
2012-10-25 How to market a new biosimilar is a key question, especially when taking into consideration the costs that are associated with developing a biosimilar. Whether… Read More »
Generics reduce England’s drug spending
2012-10-22 According to a new report from the National Health Service in England, published on 31 July 2012, despite a 3.8% increase in the number of prescriptions… Read More »
Malaysia objects to patent terms in free trade agreement
2012-10-19 Once again, the issue of patent protection and the periods of exclusivity given to originator pharmaceuticals (both small molecule and biological) has raised its ugly… Read More »
European uptake of biosimilars
2012-10-17 Despite the fact that Europe accounts for 80% of global spending on biosimilars, uptake varies significantly between different countries. This variation is mostly attributed to… Read More »
